Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

CVS Health CorpTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs State Street SPDR S&P Biotech ETF — how do they compare? CVS Health Corp trades at $94.89 (market cap $119.58B), while State Street SPDR S&P Biotech ETF trades at $158.96. The key difference: CVS Health Corp pays a 2.84% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.

CVSXBI
Market Cap
$119.58B
Sector
HealthBroad Market / Factor
52-Week High
$110.60$164.28
52-Week Low
$65.51$86.92
Enterprise Value
$181.93B
Dividend Yield
2.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.

CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.

State Street SPDR S&P Biotech ETF

XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.

The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI